<DOC>
	<DOC>NCT00396565</DOC>
	<brief_summary>The purpose of this study is to evaluate the effectiveness and safety of Extended Release Osmotic Controlled-Release Oral Delivery System (OROS) Paliperidone compared to placebo in patients with Schizophrenia. Olanzapine will be used as a reference drug in the study.</brief_summary>
	<brief_title>A Study to Evaluate Effectiveness and Safety of ER OROS Paliperidone in Patients With Schizophrenia</brief_title>
	<detailed_description>This is a multicenter, double blind (neither the patient nor the physician knows whether drug or placebo is being taken, or at what dosage), randomized (patients are assigned different treatments based on chance), placebo- and active-controlled, parallel-group study. Patients will be randomized into 1 of 3 treatment groups to receive oral dosages of Extended Release (ER) Osmotic Controlled-Release Oral Delivery System (OROS) paliperidone 6 mg, olanzapine 10 mg, or placebo. They will receive two capsules of Paliperidone ER 3 mg, placebo or Olanzapine 5 mg once daily after breakfast for 6 weeks. The study will include a screening period, followed by double-blind treatment for 6 weeks.</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Paliperidone Palmitate</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<criteria>Patients who have given their own consent in writing to participate in the study Patients diagnosed with schizophrenia according to the diagnostic criteria of DSMIV (Diagnostic and Statistical Manual of Mental Disorders, 295.30, 295.10, 295.20, 295.90, 295.60) Patients who have acute symptoms of schizophrenia Both inpatients and outpatients are acceptable A DSMIV (Diagnostic and Statistical Manual of Mental Disorders) of a mental disease diagnosis other than schizophrenia A DSMIV diagnosis of substancerelated disorder (except nicotine dependence and caffeine dependence) within 180 days before the screening test Total PANSS (Positive and Negative Syndrome System) score at the screening test &lt;70 or &gt;120 Patients treated with three or more types of antipsychotic within 28 days before the screening test Parkinson's disease (except for those with druginduced extra pyramidal symptoms) Patients with a complication of or a past history of cerebrovascular accident Patients with a complication of or a past history of diabetes mellitus</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>JNS007ER</keyword>
	<keyword>Positive and Negative Syndrome Scale (PANSS)</keyword>
	<keyword>Paliperidone</keyword>
	<keyword>Extended Release Osmotic Controlled-Release Oral Delivery System (OROS) paliperidone</keyword>
</DOC>